trial · primary record
Obinutuzumab
Lupus Nephritis
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2030-06-14 |
| Primary endpoint | Percentage of Participants who Achieve a Complete Renal Response (CRR) (AP) |
| Registry ID | NCT05039619 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:58:33.839Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05039619
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Obinutuzumab · approval
- Obinutuzumab · compound